Major Changes Ahead for FDA

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-11-02-2002, Volume 26, Issue 11

FDA is juggling momentous changes, including new leadership and the proposed transfer of oversight for therapeutic biotech drugs.

Related Content:

Quality SystemsRegulatory WatchPharmaceutical Technology-11-02-2002
Novartis’ Radioligand Therapy Gains FDA Nod for Pediatric Patients
Navigating an Uncertain Regulatory Environment for mRNA-based Products
INTERPHEX 2024: Implementing Contamination Control Strategies in Cell and Gene Therapy Facilities